Jefferies Downgrades Amphastar Pharma to Hold, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Negative 92.5%

Neg 92.5% Neu 0% Pos 0%

Jefferies analyst Dennis Ding downgrades Amphastar Pharma (NASDAQ:AMPH) from Buy to Hold and lowers the price target from $30 to $22.